Your activity: 315 p.v.
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Calculator: Center for International Blood and Marrow Transplant Research (CIBMTR) chronic graft-versus-host-disease (GVHD) risk score


Calculator: Center for International Blood and Marrow Transplant Research (CIBMTR) chronic graft-versus-host-disease (GVHD) risk score

 
Age of recipient at transplantation

<29 years (0 points)

30 to 59 years (1 point)

≥60 years (2 points)
Prior acute GVHD

None (0 points)

Present (1 point)
Time from transplant to development of chronic GVHD

≥5 months (0 points)

<5 months (1 point)
Serum bilirubin at diagnosis of chronic GVHD

≤2 mg/dL [≤34.2 mcmol/L] (0 points)

>2 mg/dL [>34.2 mcmol/L] (2 points)
Karnofsky performance score

≥80: Able to carry on normal activities without assistance (0 points)

<80: Unable to work with a need for various degrees of assistance (1 point)
Platelet count

≥100,000/microL [≥100 x 109/L] (0 points)

<100,000/microL [<100 x 109/L] (1 point)
Type of donor

HLA-identical sibling/well-matched or partially matched unrelated donor (0 points)

Other (1 point)
Disease status at transplant*

Early (0 points)

Intermediate (1 point)

Advanced (2 points)
Donor/recipient sex mismatch

Female/male (1 point)

Others (0 points)
GVHD prophylaxis

Cyclosporine plus methotrexate combination (0 points)

Other (1 point)

 
Important: Inputs must be complete to perform calculation.

 
Total criteria point count:
 

 

Interpretation

 
CIBMTR chronic GVHD risk score Risk group Overall survival (%) 5-year non-relapse mortality (%)
0 to 2 1 91 5
3 to 6 2 67 20
7 to 8 3 51 33
9 to 10 4 40 43
11 5 21 63
12 to 13 6 4 72

 
Notes
  • *Early disease: Patients undergoing transplantation in first remission of acute leukemia (AL), in the first chronic phase of chronic myelogenous leukemia (CML), or for myelodysplastic syndromes (MDS) with refractory anemia or refractory anemia with ringed sideroblasts.
  • Intermediate disease: Patients undergoing transplantation in second or later complete remission for AL, or for second or later chronic phase or accelerated phase for CML.
  • Advanced disease: Patients undergoing transplantation for primary induction failure or in relapse of AL, blast crisis for CML, or MDS with refractory anemia with excess blasts or excess blasts in transformation.
  • The risk score is based on a retrospective analysis of 5343 children and adults with chronic GVHD in the CIBMTR registry[1] and validated in subsequent retrospective studies.[2,3]
  • HLA: human leukocyte antigen.

 
Only digits 0 to 9 and a single decimal point (".") are acceptable as numeric inputs. Attempted input of other characters into a numeric field may lead to an incorrect result.

Information on this page may not appear correctly if printed.

Legal Notices and Disclaimer

All information contained in and produced by the EBMcalc system is provided for educational purposes only. This information should not be used for the diagnosis or treatment of any health problem or disease. THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER. Click here for full notice and disclaimer.

EBMcalc is Copyright © 1998-2023 Foundation Internet Services, LLC

Topic 116545 Version 5.0